Overslaan en naar de inhoud gaan
  • First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST®
  • RUCONEST® revenues increased by 8% to US$46.0 million, compared to the first quarter 2023
  • Joenja® (leniolisib) revenue of US$9.6 million, a 21% increase compared to the fourth quarter of 2023
  • On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)
  • Overall cash and marketable securities of US$203.5 million at the end of the quarter
  • Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) (view live webcast and conference call dial-in details)

Read more below

Cookies: Deze website maakt gebruik van cookies. Bekijk de cookie instellingen pagina voor meer informatie Accepteren Weigeren